In GSE35640, including 56 skin cutaneous melanoma (SKCM) patients undergoing MAGEA3 immunotherapy, the low-risk group had a higher response rate than the high-risk group (59 vs. 19%, Fig. 8A). Here, MAGEA3 is linked to cutaneous melanoma.